دورية أكاديمية
أعرض في EDS

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

التفاصيل البيبلوغرافية
العنوان: Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura
المؤلفون: Pascual, Cristina, Mingot-Castellano, María Eva, Kerguelen Fuentes, Ana E., García-Arroba, José, Cid, Joan, Jimenez, Moraima, Valcárcel, David, Gómez-Seguí, Inés, de la Rubia, Javier, Martin, Paz, Goterris, Rosa, Hernández, Luis, Tallón, Inmaculada, Varea, Sara, Fernández, Marta, García-Muñoz, Nadia, Vara, Míriam, Fernández-Zarzoso, Miguel, García-Candel, Faustino, Paciello, María Liz, García-García, Irene, Zalba, Saioa, Campuzano, Verónica, Gala, José María, Vidan, Julia, Moreno-Jiménez, Gemma, López Lorenzo, José Luis, González Arias, Elena, Freiría, Carmen, Solé, María, Ãvila Idrovo, Laura Francisca, Hernández Castellet, José Carlos, Cruz, Naylen, Lavilla, Esperanza, Pérez-Montaña, Albert, Atucha, Jon Ander, Moreno Beltrán, María Esperanza, Moreno Macías, Juan Ramón, Salinas, Ramón, del Rio-Garma, Julio
سنة النشر: 2022
المجموعة: Universitat Autònoma de Barcelona: Dipòsit Digital de Documents de la UAB
الوصف: Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P <.05) and less refractoriness (4.5% vs 14.1%; P <.05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P <.05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P <.001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX.
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
ردمك: 978-85-14-16692-4
85-14-16692-1
تدمد: 24739537
العلاقة: Blood advances; Vol. 6 Núm. 24 (December 2022), p. 6219-6227; https://ddd.uab.cat/record/282297Test; urn:10.1182/bloodadvances.2022008028; urn:oai:ddd.uab.cat:282297; urn:scopus_id:85141669213; urn:articleid:24739537v6n24p6219; urn:pmid:35930694; urn:pmc-uid:9792393; urn:pmcid:PMC9792393; urn:oai:pubmedcentral.nih.gov:9792393
الإتاحة: https://ddd.uab.cat/record/282297Test
حقوق: open access ; Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. ; https://creativecommons.org/licenses/by-nc-nd/4.0Test/
رقم الانضمام: edsbas.16EFA037
قاعدة البيانات: BASE
الوصف
ردمك:9788514166924
8514166921
تدمد:24739537